Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Launches Therapeutics Group with Former Genentech Exec at Helm

NEW YORK (GenomeWeb) – 23andMe announced today that it has created a therapeutics group headed up by former Genentech executive Richard Scheller, marking the consumer genomics firm's foray into drug development.

Scheller, who was executive VP of research and early development at Genentech, retired last December from the biotech giant. In April, he will assume his post as chief science officer and head of therapeutics at 23andMe, and will be in charge of an R&D team that will use genetic information to advance new treatments for common and rare illnesses. Key to this work will be 23andMe's database of more than 850,000 genotyped customers.

"We are putting significant resources into translating genetic information into the discovery and development of new therapies for our customers and the world," said 23andMe CEO Anne Wojcicki in a statement. 23andMe President Andy Page noted the company is working on recruiting a team of researchers for this new effort.

At Genentech, Scheller oversaw basic research in oncology, immunology, neuroscience, and infectious disease. At Stanford University for 19 years, he was a professor in the department of biological sciences and the department of molecular and cellular physiology. He was also an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center.

Two years ago, Scheller received the prestigious Albert Lasker Basic Medical Research Award for his discovery efforts elucidating the molecular and regulatory mechanisms involved in the rapid release of neurotransmitters.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.